Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hua Medicine's GKA Diabetes Treatment Passes Proof-of-Concept Trial

publication date: Oct 17, 2016
Hua Medicine of Shanghai announced positive results from a China Phase II trial of a treatment for type 2 diabetes. HMS5552 is a fourth generation glucokinase activator (GKA). Hua pointed out that the trial was the first time a GKA drug was successful as a monotherapy. Also, the fourth generation drug uses a novel scaffold to avoid hypoglycemic episodes, which plagued earlier versions of GKA treatments, and does not appear to lose efficacy as occurred with other class members. Hua hopes to start a China Phase III trial of HMS6662 in early 2017. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital